Search Results
Nov 03, 2025, 01:30 ET Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer's Disease
Therapeutics is an Icelandic drug discovery and development company established in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), a research centre at the Children's Hospital of Philadelphia. ATx leverages the transformative power of applied genomics, steering the course of drug
More news about: Arctic Therapeutics
Nov 03, 2025, 01:26 ET Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer's Disease
Therapeutics is an Icelandic drug discovery and development company established in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), a research centre at the Children's Hospital of Philadelphia. ATx leverages the transformative power of applied genomics, steering the course of drug
More news about: Arctic Therapeutics
Oct 23, 2025, 23:24 ET La FDA accorde la désignation Fast Track à AJ201, une thérapie inédite pour la maladie de Kenndy
La SBMA, ou maladie de Kennedy, est une maladie neuromusculaire rare, héréditaire et liée au chromosome X, causée par l'expansion de la répétition CAG dans le gène du récepteur des androgènes (AR). La protéine AR mutante qui en résulte contribue à la dégénérescence des muscles et des neurones par des
More news about: AnnJi Pharmaceutical Co., Ltd.
Oct 23, 2025, 00:07 ET FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease
SBMA and AJ201 SBMA, or Kennedy's disease, is a rare X-linked inherited neuromuscular disorder caused by CAG repeat expansion in the androgen receptor (AR) gene. The resulting mutant AR protein contributes to muscle and neuron degeneration through mechanisms
More news about: AnnJi Pharmaceutical Co., Ltd.
Oct 23, 2025, 00:07 ET FDA erteilt Fast-Track-Status für AJ201, eine bahnbrechende Therapie für die Kennedy-Krankheit
SBMA oder die Kennedy-Krankheit ist eine seltene, X-chromosomal vererbte neuromuskuläre Störung, die durch eine CAG-Repeat-Expansion im Androgenrezeptor-Gen (AR) verursacht wird. Das daraus resultierende mutierte AR-Protein trägt durch Mechanismen wie Zelltoxizität,
More news about: AnnJi Pharmaceutical Co., Ltd.
Oct 22, 2025, 23:18 ET FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease
SBMA and AJ201 SBMA, or Kennedy's disease, is a rare X-linked inherited neuromuscular disorder caused by CAG repeat expansion in the androgen receptor (AR) gene. The resulting mutant AR protein contributes to muscle and neuron degeneration through mechanisms
More news about: AnnJi Pharmaceutical Co., Ltd.
Oct 22, 2025, 23:08 ET La FDA otorga la designación de vía rápida para AJ201
SBMA, o enfermedad de Kennedy, es un trastorno neuromuscular hereditario poco frecuente ligado al cromosoma X, causado por la expansión de repeticiones CAG en el gen del receptor de andrógenos (RA). La proteína RA mutante resultante contribuye a la degeneración muscular y neuronal mediante mecanismos que
More news about: AnnJi Pharmaceutical Co., Ltd.
Oct 14, 2025, 08:00 ET Conagra Brands Showcases Impressive Array of Snacks at 2025 NACS Expo
CHICAGO, Oct. 14, 2025 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG), one of North America's leading branded food companies, is welcoming the annual NACS Show back to the company's hometown of Chicago. Hosted by the National
More news about: Conagra Brands, Inc.
Oct 07, 2025, 10:30 ET Veterinary Software Market worth US$2.14 billion by 2030 with 6.9% CAGR | MarketsandMarkets™
through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry and Dairy (LPD), and others. The Companion Animal Group is segmented into veterinary software, services, diagnostic imaging systems, and CAG diagnostics. The company offers veterinary software
More news about: MarketsandMarkets
Oct 01, 2025, 07:30 ET CONAGRA BRANDS REPORTS FIRST QUARTER RESULTS
CHICAGO, Oct. 1, 2025 /PRNewswire/ -- Today Conagra Brands, Inc. (NYSE: CAG) reported results for the first quarter of fiscal year 2026, which ended on August 24, 2025. All comparisons are against the prior year fiscal period,
More news about: Conagra Brands, Inc.
Sep 30, 2025, 07:30 ET Conagra Brands Announces Quarterly Dividend Payment
Sept. 30, 2025 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG) today announced that its Board of Directors approved a quarterly dividend payment of $0.35 per share of CAG common stock to be paid on November 26, 2025 to stockholders of record as of the close of business
More news about: Conagra Brands, Inc.
Sep 26, 2025, 09:00 ET COREE宣佈發現糖尿病與肥胖患者獨特微生物組生物標誌物
Putignani教授公佈了一項聯合臨床研究成果。該研究由傑梅利醫院、COREE、COREE浦項和聖心天主教大學共同開展，通過對93名肥胖或2型糖尿病患者及45名健康對照者的臨床樣本進行分析，首次在全球成功識別出這些患者特有的微生物組分佈模式。 該研究對糞便和唾液樣本進行了宏基因組分析。結果顯示，肥胖患者腸道微生物組多樣性明顯低於健康對照組。研究指出，Clostridium sp. Q和「CAG - 74」等特定細菌群，有望成為區分患者群體的潛在生物標誌物。對於2型糖尿病患者，其口腔微生物組分佈存在差異，其中Parvimonas和Aggregatibacter被認定為潛在生物標誌物。 COREE指出，此項研究不僅是科學領域的重大發現，更是未來搭建診斷平台、研發新藥以及推動糞菌移植(FMT)技術發展的關鍵支撐。
More news about: Dx&Vx
Sep 26, 2025, 09:00 ET COREE Announces Discovery of Microbiome Biomarkers Specific to Diabetes and Obesity Patients
microbiome diversity of obese patients was significantly reduced compared to healthy controls. Specific bacterial groups such as Clostridium sp. Q and "CAG-74" were highlighted as potential biomarkers capable of distinguishing patient groups. In type 2 diabetes patients, differences in oral microbiome distribution
More news about: Dx&Vx
Sep 18, 2025, 06:44 ET Apollo Hospitals at 42: Celebrates a global movement of health and happiness in homes
clinical front, Apollo Hospitals, Visakhapatnam, has been a pioneer in introducing advanced procedures and therapies: the first Coronary Angiogram (CAG), the first PTCA, IVL, and IVUS, the first Paravalvular Leak Closure, the first CABG, and the first Paediatric Heart Surgery in the region. It also performed
More news about: Apollo Hospitals
Sep 17, 2025, 08:00 ET Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
RNA-splicing platform, SKYSTAR®. SKY-0515 is designed to reduce both HTT protein and PMS1 protein, an additional key driver of somatic CAG repeat expansion and HD pathology. SKY-0515 was developed through Skyhawk's proprietary integrated platform, SKYSTAR®, and is the first
More news about: Skyhawk Therapeutics